PT  - JOURNAL ARTICLE
AU  - Manuel Rubio-Rivas
AU  - Mar Ronda
AU  - Ariadna Padulles
AU  - Francesca Mitjavila
AU  - Antoni Riera-Mestre
AU  - Carlos García-Forero
AU  - Adriana Iriarte
AU  - Jose M. Mora
AU  - Nuria Padulles
AU  - Monica Gonzalez
AU  - Xavier Solanich
AU  - Merce Gasa
AU  - Guillermo Suarez
AU  - Joan Sabater
AU  - Xose L. Perez-Fernandez
AU  - Eugenia Santacana
AU  - Elisabet Leiva
AU  - Albert Ariza-Sole
AU  - Paolo D. Dallaglio
AU  - Maria Quero
AU  - Antonio Soriano
AU  - Alberto Pasqualetto
AU  - Maylin Koo
AU  - Virginia Esteve
AU  - Arnau Antoli
AU  - Rafael Moreno
AU  - Sergi Yun
AU  - Pau Cerda
AU  - Mariona Llaberia
AU  - Francesc Formiga
AU  - Marta Fanlo
AU  - Abelardo Montero
AU  - David Chivite
AU  - Olga Capdevila
AU  - Ferran Bolao
AU  - Xavier Pinto
AU  - Josep Llop
AU  - Antoni Sabate
AU  - Jordi Guardiola
AU  - Josep M. Cruzado
AU  - Josep Comin-Colet
AU  - Salud Santos
AU  - Ramon Jodar
AU  - Xavier Corbella
TI  - Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness
AID  - 10.1101/2020.08.31.20182428
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.31.20182428
4099  - http://medrxiv.org/content/early/2020/09/01/2020.08.31.20182428.short
4100  - http://medrxiv.org/content/early/2020/09/01/2020.08.31.20182428.full
AB  - Introduction On the basis of the preliminary report from the RECOVERY trial, the use of dexamethasone or alternative corticosteroids (CS) is currently recommended in severe COVID-19 patients requiring supplemental oxygen. However, last updated recommendations have not taken a position either for or against the use of other immunomodulators such as tocilizumab (TCZ), with or without CS, since results are still limited.Methods From March 17 to April 7, 2020, a real-world observational retrospective analysis was conducted at our 750-bed university hospital to study the characteristics and risk factors for mortality in patients with severe COVID-19 treated with TCZ +/-CS, in addition to standard of care (SOC). Data were obtained from routine clinical practice, stored in electronic medical records. The main outcome was all-cause in-hospital mortality.Results A total of 1,092 COVID-19 patients were admitted during the study period. Of them, 186 (17%) were treated with TCZ, of which 129 (87.8%) in combination with CS. Of the total 186, 155 (83.3 %) patients were receiving non-invasive ventilation when TCZ +/-CS was initiated. Mean time from symptoms onset and hospital admission to TCZ use was 12 (± 4.3) and 4.3 days (± 3.4), respectively. Overall, 147 (79%) survived and 39 (21%) died. By multivariate analysis, mortality was associated with older age (HR=1.09, p<0.001), chronic heart failure (HR=4.4, p=0.003), and chronic liver disease (HR=4.69, p=0.004). The use of CS, in combination with TCZ, was the main protective factor against mortality (HR=0.26, p<0.001) in such severe COVID-19 patients receiving TCZ. No serious superinfections were observed after a 30-day follow-up.Conclusions In severe COVID-19 patients receiving TCZ due to systemic host-immune inflammatory response syndrome, the use of CS in addition to TCZ therapy, showed beneficial effect in preventing in-hospital mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding or sponsorship was received for this study or publication of this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study received the ethical approval by the Research Ethics Committee of Bellvitge University Hospital (PR145/20).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.